Here’s what you need to know.
1. NQO1 and HIF-1a protect the body from free radicals and environmental toxins.
2. In many cancers these enzymes are present in overabundant quantities. According to a release, elevated NQO1 levels are associated with poor prognoses in breast, colon, cervical, lung and pancreatic cancer.
3. Dr. Kim conducted a series of experiments to see what protein would interact with HIF-1a. They found that NQO1 will bind with HIF-1a to form a complex.
4. In a cancer cell when the two bind, NQO1 regulates HIF-1a by stabilizing it, preventing it from downgrading.
5. The researchers examined colorectal cancer cells and found a high correlation between NQO1 and HIF-1a confirming that the enzymes interact.
6. The researchers performed a follow-up study where they eliminated NQO1 in colorectal and breast cancer cells and injected them into mice with immune systems capable of growing human cancer. They saw the tumor levels drop in the mice that received cancer cells without NQO1.
More articles on gastroenterology/endoscopy:
FDA awards 510(k) clearance to DiLumen: 4 things to know
GI leader to know: Dr. Sidney Neimark of the Digestive Center of the Palm Beaches
IBD monitoring index may pave the way for GI mobile health: 3 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
